Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

222

Enrollment

OTHER

Sponsor class

Conditions

Graft Rejection

Interventions

DRUG: Alemtuzumab
DRUG: Anti-Thymocyte Globulin

Sponsor

Wake Forest University Health Sciences